SMAD5 and cancer: Reduced SMAD1 and SMAD4 expression was seen across all cancer subtypes, but SMAD5 was differentially expressed: it was downregulated in canonical tumours (n = 149), but was retained and modestly upregulated in poor‐prognosis, mesenchymal tumours (n = 78) (Figure 4C).